Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) EBT Margin (2016 - 2025)

Historic EBT Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 92.91%.

  • Lineage Cell Therapeutics' EBT Margin fell 135000.0% to 92.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 296.07%, marking a year-over-year decrease of 661600.0%. This contributed to the annual value of 195.62% for FY2024, which is 646600.0% up from last year.
  • Lineage Cell Therapeutics' EBT Margin amounted to 92.91% in Q3 2025, which was down 135000.0% from 698.95% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' EBT Margin peaked at 56.02% during Q4 2021, and registered a low of 969.73% during Q2 2021.
  • Moreover, its 5-year median value for EBT Margin was 260.14% (2023), whereas its average is 318.95%.
  • Per our database at Business Quant, Lineage Cell Therapeutics' EBT Margin soared by 12693600bps in 2021 and then crashed by -3885200bps in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' EBT Margin stood at 56.02% in 2021, then crashed by -493bps to 332.22% in 2022, then skyrocketed by 32bps to 225.77% in 2023, then skyrocketed by 50bps to 113.32% in 2024, then rose by 18bps to 92.91% in 2025.
  • Its EBT Margin was 92.91% in Q3 2025, compared to 698.95% in Q2 2025 and 401.26% in Q1 2025.